Table 2.
Subgroup analyses for the two examples.
| Trial Group | # trials |
Q, P-value,  (%)
|
Fixed Effect HR (CI) P-value | Random Effects HR (CI) P-value |
|---|---|---|---|---|
| NSCLC data | ||||
| all | 11 | 39.6 (1.97e-05) 74.8 | 0.84 (0.74-0.95) 5.42e-03 | 0.77 (0.59-0.99) 0.042 |
| Cisplatin | 8 | 22.2 (2.34e-03) 68.5 | 0.73 (0.63-0.85) 6.63e-05 | 0.70 (0.53-0.93) 0.014 |
| Qint = 39.62 - (22.20 + 8.72) = 8.70 (p = 0.003) | ||||
| all* | 11 | 0.84 (0.61-1.16) 0.21 | ||
| Cervix data | ||||
| >14 days | 11 | 12.76 (0.24) 22 | 1.25, (1.07,1.46) 0.005 | 1.27 (1.06,1.53) 0.0099 |
| ≤ 14 days | 7 | 20.74 (0.002) 71 | 0.83, (0.69,1.00) 0.046 | 0.87 (0.60,1.25) 0.44 |
| Qint = 44.48 - (12.76 + 20.74) = 10.98 (p = 9e-04) | ||||
Qint denotes the subgroup interaction test statistic. * denotes the Henmi-Copas analysis: which puts a 'random effects' confidence interval around the fixed effects estimate.